Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Newave Pharmaceutical Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 5 distinct examiners, meaning that every pending application is being reviewed by a different official. The portfolio is active across 3 distinct art units, which suggests that the company's pharmaceutical innovations are being evaluated by several different specialized groups within the patent office.
STOCKTON, LAURA LYNNE is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. Since the 5 pending office actions are spread across 5 distinct examiners, the company does not have a primary point of contact for its prosecution efforts. Managing 5 distinct examiners across 3 distinct art units requires a versatile approach to the Biotechnology & Pharmaceuticals sector, as the applicant must address the specific technical concerns and procedural requirements of multiple different examination teams simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18971214 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | STOCKTON, LAURA LYNNE | — |
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | — |
| 18721999 | BCL-2 INHIBITORS | SCHMITT, MICHAEL J | — |
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | — |
| 18033481 | INHIBITORS OF BTK | FERGUSON, JALISA HOLMES | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1624 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971214 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | STOCKTON, LAURA LYNNE | 1626 | §112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | 1624 | §112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18721999 | BCL-2 INHIBITORS | SCHMITT, MICHAEL J | 1629 | Other | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | 1626 | §101§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18033481 | INHIBITORS OF BTK | FERGUSON, JALISA HOLMES | 1626 | §112 | Final Rejection | — | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNewave Pharmaceutical Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Laura Lynne Stockton has the most, with 1 of Newave Pharmaceutical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
